Trial Profile
Efficacy and tolerability of roflumilast added to triple therapy in patients with severe COPD and frequent exacerbations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2015
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 13 Nov 2015 New trial record